OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today
that Colin Goddard, Ph.D., Chief Executive Officer of OSI
Pharmaceuticals will present at the Morgan Stanley Healthcare
Conference in Miami, Fla. on Friday, May 6, 2005 at 9:30am Eastern
Time. Dr. Goddard will provide an overview on the Company's product
portfolio and business developments.
The presentation will be webcast live and may be accessed by visiting OSI's website at www.osip.com. A replay of the webcast will also be available on the Company's website until Friday, May 13, 2005.
About OSI Pharmaceuticals
OSI Pharmaceuticals is a leading biotechnology company primarily focused on the discovery, development and commercialization of high-quality pharmaceutical products that extend life or improve the quality of life for cancer and diabetes patients worldwide. OSI's primary business remains oncology, but the Company has a second business interest in the area of diabetes through its subsidiary, Prosidion Limited, based in the United Kingdom. Tarceva(TM) (erlotinib), OSI's flagship product, is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitor to have demonstrated the ability to improve survival in non-small cell lung cancer and pancreatic cancer. OSI exclusively markets Novantrone(R) (mitoxantrone concentrate for injection) for the approved oncology indications and markets Gelclair(R) Bioadherent Oral Gel for the relief of pain associated with oral mucositis. For additional information about the company, please visit http://www.osip.com.
The presentation will be webcast live and may be accessed by visiting OSI's website at www.osip.com. A replay of the webcast will also be available on the Company's website until Friday, May 13, 2005.
About OSI Pharmaceuticals
OSI Pharmaceuticals is a leading biotechnology company primarily focused on the discovery, development and commercialization of high-quality pharmaceutical products that extend life or improve the quality of life for cancer and diabetes patients worldwide. OSI's primary business remains oncology, but the Company has a second business interest in the area of diabetes through its subsidiary, Prosidion Limited, based in the United Kingdom. Tarceva(TM) (erlotinib), OSI's flagship product, is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitor to have demonstrated the ability to improve survival in non-small cell lung cancer and pancreatic cancer. OSI exclusively markets Novantrone(R) (mitoxantrone concentrate for injection) for the approved oncology indications and markets Gelclair(R) Bioadherent Oral Gel for the relief of pain associated with oral mucositis. For additional information about the company, please visit http://www.osip.com.